Hanyu Pharmaceutical’s glatiramer acetate injection receives FDA approval in the United States.
February 13, 2026
Source: drugdu
33
Shanghai Securities News China Securities(Reporter He Xinyi) On the evening of February 12, Hanyu Pharmaceutical...The announcement stated that the company received an abbreviated new drug application certificate for glatiramer acetate injection from the U.S. Food and Drug Administration (FDA).
The announcement indicates that glatiramer acetate is an immunomodulatory drug used to treat relapsing-remitting multiple sclerosis (MS). It is a synthetic polypeptide preparation that modulates abnormal autoimmune responses by mimicking the structure of myelin basic proteins, thereby reducing the attack on the myelin sheath of the central nervous system.
Hanyu Pharmaceutical stated that the approval of glatiramer acetate will further enrich the company's overseas product pipeline and expand the company's pharmaceutical market in the United States. The company will actively promote the sales of the drug in overseas markets, thereby positively promoting the company's future performance growth and industry position.
https://finance.eastmoney.com/a/202602123649504078.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Rising Star in Oral Weight Loss! Hengrui’s GLP 1R/GIPR Agonist Succeeds in Phase II Study February 13, 2026
- adjuvant therapy for breast cancer February 13, 2026
- The approval of telpopril monotherapy for type 2 diabetes has driven an upgrade in the management paradigm February 13, 2026
- Oral insulin launch fails; China Resources Pharmaceutical plans to sell Tianmai Biotechnology February 13, 2026
- Global ADC market size $16.5 billion February 13, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
